SLSimeng Liu

Simeng Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simeng Liu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Pengyuan Zheng

    Henan Key Laboratory of Helicobacter Pylori and Microbiota and Gastrointestinal Cancer, Marshall B. J. Medical Research Center of Zhengzhou University, The Fifth Affiliated Hospital of Zhengzhou University

    7 shared publications
  • Huayuan Xi

    Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University; Institute of Rehabilitation Medicine, Henan Academy of Innovations in Medical Science; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, People's Republic of China

    5 shared publications
  • Huijuan Wen

    Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University; Institute of Rehabilitation Medicine, Henan Academy of Innovations in Medical Science; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, People's Republic of China

    5 shared publications
  • Xia Xue

    Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University; Institute of Rehabilitation Medicine, Henan Academy of Innovations in Medical Science; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, People's Republic of China

    5 shared publications
  • Xiangdong Sun

    Henan Key Laboratory of Helicobacter pylori & Microbiota and Gastrointestinal Cancer, Marshall Medical Research Center, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China

    5 shared publications
  • Fazhan Li

    Henan Key Laboratory for Helicobacter Pylori and Digestive Tract Microecology, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China

    4 shared publications

Latest Publications

  • Multi‐Omic Analysis of Putative Cellular Senescence‐Associated Genes on the Risk of Pan‐Cancer

    by Bin Liu, Weidong Wu, Chang Liu, Pengya Feng, Simeng Liu, Shanshan Gong, Yingying Li, Ya Li, Jun Mi, Pengyuan Zheng, et al.

    Cellular senescence plays a critical role in physiological and pathological processes. This study aims to elucidate the contribution of cellular senescence‐related genes to disease etiology. We investigated a cohort study of 439,501 individuals, which included 22 cancers and 9 non‐cancer diseases. We found that HLA‐E and HLA‐G ‐associated senescence in epithelial and immune cells were specific oncogenic factors for prostate and lung cancers. MAP2K4 was implicated as a risk factor for breast cancer, while ZFP36L1 and STAT3 were associated with a reduced risk of inflammatory bowel disease (IBD). Notably, ETS2 ‐mediated inhibition of the senescence‐associated secretory phenotype (SASP) was associated with decreased disease risk. Furthermore, single‐cell level analysis confirmed that the dynamics of these marked gene expressions in immune cells was related to reduced disease risk, while upregulation in epithelial cells correlated with increased disease risk. In parallel, co‐localization analyses corroborated these associations, explaining potential regulatory mechanisms underlying disease risk variants. These findings enhance our understanding of how cellular senescence works on disease susceptibility and provide potential targets for therapeutic interventions and precision medicine approaches.

  • Open Access

    The STAT3-CCND2 Axis Drives a Proliferative Metaplastic Precursor Population in Gastric Intestinal Metaplasia.

    by Fazhan Li, Huijuan Wen, Feifei Ren, Pengyuan Zheng, Simeng Liu

    Gastric intestinal metaplasia (GIM) is a crucial precancerous lesion with ill-defined drivers, and identifying regulators of its early proliferation and reprogramming is key to interception. We integrated epigenomic-transcriptomic analysis of human GIM and normal tissues, validated targets via dual-luciferase assay, and mapped cellular heterogeneity by single-cell RNA sequencing of patient-derived gastric organoids. Functional validation using organoids included STAT3 knockdown assessed by qRT-PCR and immunofluorescence. STAT3 was identified as a top regulator of hypomethylated, upregulated genes in GIM and directly transactivated CCND2. Single-cell analysis revealed a dominant proliferative "Cycling GIM-precursor" population co-expressing STAT3/CCND2. STAT3 knockdown reduced CCND2 and intestinal markers (CDX2, MUC2) in GIM organoids. The STAT3-CCND2 axis is central to early GIM pathogenesis, offering targets for early detection and chemoprevention of gastric cancer.


  • Open Access

    A novel sulfonamide derivative suppresses gastrointestinal cancer progression by targeting Axin2 and β-catenin

    by Xiaojie Li, Huijuan Wen, Le Chang, Xia Xue, Huayuan Xi, Ruoyu Hu, Mengke Rong, Pengyuan Zheng, Simeng Liu

    Gastrointestinal cancer is a major global health risk with rising incidence and limited effective therapeutic options. Despite advancements in diagnostics and therapies, the aggressive nature of these malignancies make novel therapeutic strategies essential. This study synthesized and evaluated a novel sulfonamide derivative, compound 2406, for its antiproliferative effects in gastrointestinal cancer cell lines (EC-9706, SGC-7901, and HT-29). Molecular docking and biological assays were conducted to assess its potential binding and interaction with β-tubulin and the Wnt/β-catenin signaling pathway, with a focus on EC-9706 and HT-29 cell lines. Compound 2406 significantly inhibited tumor cell invasion, migration, and colony formation. It induced G2/M phase cell cycle arrest in EC-9706 and HT-29 cells, reducing cellular proliferation. Molecular docking and in vitro experiments confirmed that compound 2406 interfered with β-tubulin cytoskeletal integrity and suppressed Wnt/β-catenin signaling, which is critical for tumor progression. These findings highlight the therapeutic potential of compound 2406 as a novel anticancer agent targeting β-tubulin and Wnt/β-catenin signaling in gastrointestinal cancer. Further in vivo studies would be warranted to validate its efficacy and clinical applicability.


  • Open Access

    Identifying the signature of NAD+ metabolism-related genes for immunotherapy of gastric cancer

    by Huijuan Wen, Yang Mi, Fazhan Li, Xia Xue, Xiangdong Sun, Pengyuan Zheng, Simeng Liu


  • Open Access

    Clostridium butyricum regulates intestinal barrier function via trek1 to improve behavioral abnormalities in mice with autism spectrum disorder

    by Simeng Liu, Huayuan Xi, Xia Xue, Xiangdong Sun, Huang Huang, Dongjun Fu, Yang Mi, Yongzheng He, Pingchang Yang, Youcai Tang, et al.

    Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder that has been found to be associated with dysregulation of gastrointestinal functions and gut microbial homeostasis (the so-called “gut-brain axis”). ASD is often accompanied by poor performances in social interaction and repetitive behaviors. Studies on the gut-brain axis provide novel insights and candidate targets for ASD therapeutics and diagnosis. Based on the ASD mice model, this work aims to reveal the mechanisms behind the interaction of intestinal barrier function and probiotics in ASD mouse models. Results: We found an altered intestinal barrier in both BTBR T+ Itpr3tf/J (BTBR) and valproic acid (VPA) mice, including increased intestinal permeability, decreased expression of intestinal tight junction proteins (claudin1, claudin3, and occludin), and increased levels of IL-6, TNF-α, and IFN-γ. Based on intestinal microbial alternation, C. butyricum can drive reduced expression of histone deacetylases 1 (HDAC1) and enhanced intestinal barrier function, significantly promoting behavioral abnormalities of ASD in BTBR mice. In parallel, we confirmed that C. butyricum was involved in the regulation of intestinal function by the Trek1 channel, indicating that it is a target of C. butyricum/butyric acid to improve intestinal barrier function in ASD mice. Conclusions: Our finding provides solid evidence for the gut microbiota involved in ASD through the brain-gut axis. In addition, the probiotics C. butyricum hold promise to improve gut health and ameliorate behavioral abnormalities associated with ASD.


  • Open Access

    Revealing the role of metformin in gastric intestinal metaplasia treatment

    by Ruoyu Hu, Xia Xue, Xiangdong Sun, Yang Mi, Huijuan Wen, Huayuan Xi, Fuhao Li, Pengyuan Zheng, Simeng Liu

    Objective: Gastric intestinal metaplasia (IM) is a precancerous stage associated with gastric cancer. Despite the observed beneficial effects of metformin on IM, its molecular mechanism remains not fully elucidated. This study aims to reveal the effects and potential mechanisms of metformin in treating IM based on both bioinformatics and in vivo investigations.Methods: The seven public databases (GeneCards, DisGeNET, OMIM, SuperPred, Pharm Mapper, Swiss Target Prediction, TargetNet) were used in this work to identify targeted genes related to intestinal metaplasia (IM) and metformin. The shared targeted genes between metformin and IM were further analyzed by network pharmacology, while the interactions in-between were investigated by molecular docking. In parallel, the therapeutic effect of metformin was evaluated in IM mice model, while the core targets and pathways effected by metformin were verified in vivo.Results: We screened out 1,751 IM-related genes and 318 metformin-targeted genes, 99 common genes identified in between were visualized by constructing the protein-protein interaction (PPI) network. The top ten core targeted genes were EGFR, MMP9, HIF1A, HSP90AA1, SIRT1, IL2, MAPK8, STAT1, PIK3CA, and ICAM1. The functional enrichment analysis confirmed that carcinogenesis and HIF-1 signaling pathways were primarily involved in the metformin treatment of IM. Based on molecular docking and dynamics, we found metformin affected the function of its targets by inhibiting receptor binding. Furthermore, metformin administration reduced the progression of IM lesions in Atp4a−/− mice model significantly. Notably, metformin enhanced the expression level of MUC5AC, while inhibited the expression level of CDX2. Our results also showed that metformin modulated the expression of core targets in vivo by reducing the activity of NF-κB and the PI3K/AKT/mTOR/HIF-1α signaling pathway.Conclusion: This study confirms that metformin improves the efficacy of IM treatment by regulating a complex molecular network. Metformin plays a functional role in inhibiting inflammation/apoptosis-related pathways of further IM progression. Our work provides a molecular foundation for understanding metformin and other guanidine medicines in IM treatment.


  • Open Access

    Exploring the potential of thiophene derivatives as dual inhibitors of β-tubulin and Wnt/β-catenin pathways for gastrointestinal cancers in vitro

    by Lina Fu, Fuhao Li, Xia Xue, Huayuan Xi, Xiangdong Sun, Ruoyu Hu, Huijuan Wen, Simeng Liu


  • Open Access

    Revealing the pathogenesis of gastric intestinal metaplasia based on the mucosoid air-liquid interface

    by Simeng Liu, Huijuan Wen, Fazhan Li, Xia Xue, Xiangdong Sun, Fuhao Li, Ruoyu Hu, Huayuan Xi, Francesco Boccellato, Thomas F Meyer, et al.

    Background: Gastric intestinal metaplasia (GIM) is an essential precancerous lesion. Although the reversal of GIM is challenging, it potentially brings a state-to-art strategy for gastric cancer therapeutics (GC). The lack of the appropriate in vitro model limits studies of GIM pathogenesis, which is the issue this work aims to address for further studies. Method: The air-liquid interface (ALI) model was adopted for the long-term culture of GIM cells in the present work. This study conducted Immunofluorescence (IF), quantitative real-time polymerase chain reaction (qRT-PCR), transcriptomic sequencing, and mucoproteomic sequencing (MS) techniques to identify the pathways for differential expressed genes (DEGs) enrichment among different groups, furthermore, to verify novel biomarkers of GIM cells. Result: Our study suggests that GIM-ALI model is analog to the innate GIM cells, which thus can be used for mucus collection and drug screening. We found genes MUC17, CDA, TRIM15, TBX3, FLVCR2, ONECUT2, ACY3, NMUR2, and MAL2 were highly expressed in GIM cells, while GLDN, SLC5A5, MAL, and MALAT1 showed down-regulated, which can be used as potential biomarkers for GIM cells. In parallel, these genes that highly expressed in GIM samples were mainly involved in cancer-related pathways, such as the MAPK signal pathway and oxidative phosphorylation signal pathway. Conclusion: The ALI model is validated for the first time for the in vitro study of GIM. GIM-ALI model is a novel in vitro model that can mimic the tissue micro-environment in GIM patients and further provide an avenue for studying the characteristics of GIM mucus. Our study identified new markers of GIM as well as pathways associated with GIM, which provides outstanding insight for exploring GIM pathogenesis and potentially other related conditions.


  • Open Access

    Comprehensive Analysis of Colorectal Cancer Immunity and Identification of Immune-Related Prognostic Targets

    by Huijuan Wen, Fazhan Li, Ihtisham Bukhari, Yang Mi, Chenxu Guo, Bin Liu, Pengyuan Zheng, Simeng Liu

    Colorectal cancer (COAD) is ranked as the third most common cancer and second in terms of cancer-related deaths worldwide. Due to its poor overall survival and prognosis, the incidents of COAD are significantly increasing. Although treatment methods have greatly been improved in the last decade, it is still not good enough to have satisfactory treatment outcomes. In recent years, immunotherapy has been successful to some extent in the treatment of many cancers but still, many patients do not respond to immunotherapy. Therefore, it is essential to have a deeper understanding of the immune characteristics of the tumor microenvironment and identify meaningful immune targets. In terms of immune targets, COAD has been poorly explored; thus, in the current study, based on the immune cell infiltration score and differentially expressed genes, COAD tumors were classified into hot and cold tumors. The Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis was used to identify hub genes, construct a prognostic model, and screen potential immune targets. In total, 12 genes (CLK3, CYSLTR2, GJA10, CYP4Z1, FAM185A, LINC00324, EEF1A1P34, EEF1B2P8, PTCSC3, MIR6780A, LINC01666, and RNU6.661P) differentially expressed between hot and cold tumors were screened out. Among them, CYSLTR2 was considered as a potential candidate gene, because it showed a significant positive correlation with immune cell infiltration and immune checkpoints (PDCD1, CD274, and CTLA4). Finally, we constructed and validated a new prognostic model for COAD showing 0.854 AUC for the ROC curve, and these results provide sufficient potential to choose CYSLTR2 as an important immune target for the prognosis of COAD.